Across 100 European inflammatory bowel disease (IBD) Phase II and Phase III trials, 67 trials (67.0%) listed CRO support. IQVIA was the most frequent CRO group, appearing in 23/67 CRO-supported trials (34.3%), followed by ICON / PRA in 18/67 (26.9%) and Labcorp in 17/67 (25.4%). CRO need rises sharply with operational scale: 28/30 trials with 41+ sites (93.3%) and 39/43 trials with 8+ countries (90.7%) used CROs.
Among the 67 CRO-supported trials, IQVIA appeared in 23 trials (34.3%), ICON / PRA in 18 (26.9%), and Labcorp in 17 (25.4%). CRO roles are non-exclusive: a single trial can list multiple CROs, vendors, central labs, eCOA providers, and operational partners.
The IBD CRO market is led by large full-service and operational CRO networks, but the top list also includes specialist functional partners such as Labcorp, Endpoint Clinical, ERT / Clario, Almac, Medidata, Alimentiv, Bioclinica, Signant Health, and WCG Clinical. For sponsors planning CTIS submissions across multiple EU/EEA countries, CRO selection is often a multi-vendor operating model rather than a single outsourced provider decision.
CRO support was present in 38/50 Phase III trials (76.0%), compared with 25/44 Phase II trials (56.8%). By indication, mixed ulcerative colitis (UC) and Crohn’s disease programs had the highest CRO use at 9/12 trials (75.0%), followed by Crohn’s disease at 26/37 (70.3%) and UC at 32/49 (65.3%).
The phase signal is stronger than the disease signal. Phase III execution, EU/EEA country roll-out, and larger enrollment planning appear to create the highest CRO need, while UC and Crohn’s disease both show substantial outsourcing levels.
In CTIS country-mapped trials, CRO support increased from 3/30 single-country trials (10.0%) to 14/16 trials with 4–7 countries (87.5%) and 39/43 trials with 8+ countries (90.7%). The 8+ country group is the clearest point where CRO support becomes nearly standard.
For IBD sponsors, the main CTIS outsourcing inflection point is not a specific country but the number of simultaneous Part II country submissions and local site activations. Once a trial spans 4+ countries, CRO support becomes the dominant operating model.
CRO support was present in only 3/19 trials with 1–5 sites (15.8%) and 1/7 trials with 6–15 sites (14.3%). It rose to 21/30 trials with 16–40 sites (70.0%) and 28/30 trials with 41+ sites (93.3%).
The practical outsourcing trigger is site-management burden. Trials with 41+ sites almost always require external support for monitoring, site activation, vendor coordination, regulatory operations, eCOA, central reading, central labs, or supply functions.
CRO support increased from 10/21 trials with ≤50 participants (47.6%) to 21/34 trials with 51–150 participants (61.8%), 15/21 trials with 151–300 participants (71.4%), and 10/13 trials with 301+ participants (76.9%).
Enrollment size increases CRO use, but geography and site count are more decisive. A 300+ participant IBD trial may still be operationally concentrated, while a 16+ country or 41+ site trial creates multi-country CTIS, monitoring, contracting, site, and vendor complexity.
The most common outsourced functions were operational CRO / monitoring / regulatory work in 27/67 CRO-supported trials (40.3%), central lab / PK / bioanalysis in 23/67 (34.3%), eCOA / ePRO / eDiary / EDC / eConsent in 21/67 (31.3%), imaging / central reading / endoscopy in 19/67 (28.4%), and safety / adjudication / DMC / emergency support in 16/67 (23.9%).
IBD outsourcing is not only classic full-service trial management. The disease area creates recurring functional demand for central labs, pharmacokinetics (PK), immunogenicity, electronic clinical outcome assessment (eCOA), patient-reported outcomes (PROs), endoscopy/image reading, safety adjudication, and CTIS-aligned operational coordination.
Poland had the largest IBD trial footprint with 60 trials, 611 CTIS-listed sites, and 3,254 participants; 53/60 Polish-country trial entries (88.3%) came from CRO-supported trials. France followed with 56 trials, 372 sites, and 2,329 participants; Germany had 49 trials, 284 sites, and 1,530 participants.
| Country | CRO-supported trials | Sites | Participants | Avg Part II processing |
|---|---|---|---|---|
| Poland | 53/60 (88.3%) | 611 | 3254 | 232.3 days |
| France | 42/56 (75.0%) | 372 | 2329 | 261.0 days |
| Italy | 44/49 (89.8%) | 312 | 847 | 232.8 days |
| Germany | 42/49 (85.7%) | 284 | 1530 | 202.5 days |
| Belgium | 42/47 (89.4%) | 180 | 489 | 213.9 days |
| Spain | 39/43 (90.7%) | 178 | 475 | 225.6 days |
| Hungary | 37/41 (90.2%) | 168 | 604 | 224.3 days |
| Czechia | 39/39 (100.0%) | 166 | 665 | 222.0 days |
| Romania | 21/28 (75.0%) | 120 | 736 | 233.7 days |
| Bulgaria | 25/28 (89.3%) | 107 | 407 | 200.2 days |
For EU submission planning, Poland, France, Germany, Italy, Spain, Belgium, Hungary, and Czechia should be treated as high-operational-load CTIS countries in IBD. CRO-supported country authorizations averaged 209.2 days across 514 country authorization entries, close to 212.1 days across 77 non-CRO country entries, suggesting CRO use tracks geographic and site burden more than faster authorization time.
Pharmaceutical-company sponsors used CROs in 67/79 trials (84.8%), while hospital, laboratory/research, and educational sponsors used CROs in 0/21 trials (0.0%). CRO-supported trials also listed an average of 9.4 third parties per trial, compared with 0.6 third parties in non-CRO trials.
The IBD outsourcing buyer is most often a pharmaceutical sponsor running a multi-country biologic or advanced-therapy program. Monoclonal-antibody trials used CROs in 32/39 trials (82.1%), while small-molecule trials used CROs in 16/27 trials (59.3%).
In European IBD Phase II/III trials, CRO support is most strongly associated with site count, country count, pharma sponsorship, and Phase III execution. The clearest capacity triggers are 41+ sites, where 28/30 trials (93.3%) used CROs, and 8+ countries, where 39/43 trials (90.7%) used CROs. The most active CRO groups are IQVIA, ICON / PRA, and Labcorp, while the most outsourced functions are operational CRO / monitoring / regulatory work, central labs / PK / bioanalysis, eCOA/ePRO, central reading/endoscopy, and safety or adjudication support.